A study to determine the ability of a blood test for B-type Natriuretic Peptide signal peptide (BNP-SP) to act as an early indicator in Acute Coronary Syndrome (ACS)).
Not Applicable
Recruiting
- Conditions
- Acute Coronary SyndromeCardiovascular - Coronary heart disease
- Registration Number
- ACTRN12609000057280
- Lead Sponsor
- Health Research Council of New Zealand
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
Male or female
18 years of age or older
presenting to hospital with possible acute coronary syndrome
Exclusion Criteria
Unable to give informed consent
Unable to comply with study requirements
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome of this proposal will be the identification of B-type Natriuretic Peptide signal peptide (BNP-SP) as a novel, specific biomarker of acute cardiac injury. For each blood sample, we will measure plasma BNP-SP as well as the standard serial biomarker concentrations of troponin, creatine kinase and myoglobin.[Additional assessment time points at 3, 6-12 & 48 hours and 30 days and 6 months post admission ]
- Secondary Outcome Measures
Name Time Method The secondary outcome will be the potential identification of a new class of circulating biomarkers that may have diagnostic potential in pathophysiology. For each blood sample, we will measure plasma BNP-SP as well as the standard serial biomarker concentrations of troponin, creatine kinase and myoglobin[Additional assessment time points at 3, 6-12 & 48 hours and 30 days and 6 months post admission ]